Related Experiment Video
Updated: May 19, 2026

Assessing Murine Resistance Artery Function Using Pressure Myography
Published on: June 7, 2013
Bradykinin β2 receptor -58T/C gene polymorphism and essential hypertension: a meta-analysis
Yan-yan Li1, Hui Zhang, Jian Xu
1Department of Geriatrics, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. lyynjmu123@126.com
Background:
Research has shown that bradykinin β(2) receptor (BDKRB2) -58T/C gene polymorphism is correlated with the risk of essential hypertension (EH), but the results remain inconclusive.
Objective And Methods:
The objective of this study was to explore the association between BDKRB2-58T/C gene polymorphism and EH. A meta-analysis of 11 studies with 3882 subjects was conducted. Pooled odds ratios (ORs) for the association between BDKRB2-58T/C gene polymorphism and EH and their corresponding 95% confidence intervals (CIs) were estimated using the random effects model.
Results:
The BDKRB2-58T/C gene polymorphism was significantly correlated with EH under an allelic genetic model (OR = 1.24, 95% CI = 1.05-1.46; P = 0.01), a dominant genetic model (OR = 0.65, 95% CI = 0.47-0.90; P = 0.01), a recessive genetic model (OR = 1.146, 95% CI = 1.035-1.269; P = 0.009), a homozygote genetic model (OR = 1.134, 95% CI = 1.048-1.228; P = 0.002), and a heterozygote genetic model (OR = 1.060, 95% CI = 1.009-1.112; P = 0.019).
Conclusions:
The BDKRB2-58T/C gene polymorphism is associated with increased EH risk. The results of this study suggest that carriers of the -58C allele are susceptible to EH.
Related Concept Videos
Antihypertensive Drugs: Action of β1 Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Hypertension II: Pathophysiology
